Abiopharma

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Akanda Corp (AKAN) Files Form 6-K

Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care

Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Cybin - Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçets Disease Published in Rheumatology (Oxford)

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion